Bioinspiration

American Institute of Chemical Engineers Honors Organizations and Leaders for Empowering Possibilities

Retrieved on: 
Monday, December 11, 2023
Workforce, Senior, Hansjörg Wyss, Bionics, Corporate communication, Chevron Phillips Chemical, Chemical engineering, Atmosphere of Earth, Research, System, Dow, Chemistry, Multiple sclerosis, American Institute, Diabetes, AdvanSix, Engineering, ExxonMobil, Honeywell, Cancer, Air Products, Bioinspiration, Gala, Medicine, Chemical industry, Partnership, Corporation, Biological engineering, Harvard University, Management

NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The American Institute of Chemical Engineers (AIChE) celebrated the contributions of the companies and the leaders of AdvanSix Inc. and Air Products, and showcased the good works of chemical engineers and their employers, at the 2023 AIChE Gala, held December 7 in New York City.

Key Points: 
  • NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The American Institute of Chemical Engineers (AIChE) celebrated the contributions of the companies and the leaders of AdvanSix Inc. and Air Products, and showcased the good works of chemical engineers and their employers, at the 2023 AIChE Gala, held December 7 in New York City.
  • The award for AdvanSix was accepted by Erin Kane, the company’s President and Chief Executive Officer.
  • In accepting the award at the gala, Kane shared “AdvanSix is grounded in our focus on good chemistry.
  • Mitragotri thanked the AIChE foundation for recognizing drug delivery as a prominent contribution of chemical engineers to the field of medicine.

Empowering Possibility: AIChE’s 2023 Gala will Celebrate Chemical Engineering Organizations and Their Leaders

Retrieved on: 
Wednesday, May 31, 2023
Workforce, Diabetes, Engineering, American Institute of Chemical Engineers, Harvard University, AdvanSix, Cancer, Nutrient, Research, The Pierre, Bionics, Multiple sclerosis, Organization, Chemical engineering, Hansjörg Wyss, Nylon 6, Biological engineering, Air Products, Hiller, Bioinspiration, Transport, Gala, American Institute, Skin, The, Management

Organized around the theme “Empowering Possibilities,” the gala will spotlight the contributions of AdvanSix Inc., a U.S.-based diversified chemistry company that produces Nylon 6 and a portfolio of plant nutrients and chemical intermediates used by industry.

Key Points: 
  • Organized around the theme “Empowering Possibilities,” the gala will spotlight the contributions of AdvanSix Inc., a U.S.-based diversified chemistry company that produces Nylon 6 and a portfolio of plant nutrients and chemical intermediates used by industry.
  • AdvanSix will be represented at the gala by Erin Kane, the company’s President and Chief Executive Officer.
  • Seifi Ghasemi, Air Products’s Chairman, President, and Chief Executive Officer, is slated to accept the honor at the gala.
  • For the latest information about the AIChE Gala and to reserve your seat, visit www.aiche.org/gala .

Harvard’s Wyss Institute and Collaborative Fund cofound research lab to fund technology to combat climate change

Retrieved on: 
Tuesday, May 23, 2023
Wyss Institute for Biologically Inspired Engineering, Plastic, Collaborative Fund, Bakalar, Food, North American Vascular Biology Organization, Dandelion Energy, Partnership, Education, Research, Harvard University, Innovation system, Innovation, Harvard John A. Paulson School of Engineering and Applied Sciences, Modern Meadow, Harvard Medical School, Commonwealth Fusion Systems, Nature, Climate change, Patent, Robotics, Head, Wyss Institute, Applied science, Water, Judah, Bioinspiration, Growth, Climate, Hospital, Textile, Laboratory, Synthetic biology, Renewable energy, Management, Engineering, Wyss

Collaborative Fund , a New York-based venture fund, is a leading source of capital and strategic support for entrepreneurs, businesses, and protocols pushing the world forward.

Key Points: 
  • Collaborative Fund , a New York-based venture fund, is a leading source of capital and strategic support for entrepreneurs, businesses, and protocols pushing the world forward.
  • As part of the alliance, Collaborative Fund will provide $15 million to create a Laboratory for Sustainable Materials Research and Innovation at the Wyss Institute to support research into transformational technology with strong commercial potential.
  • Collaborative Fund has over a decade of experience investing in climate technology and recently launched a dedicated $200M climate fund, Collab SOS , to fuel a more sustainable economy across materials, ingredients, energy, and supply chains.
  • When it comes to climate change, there’s no time to waste,” said Sophie Bakalar, partner at Collaborative Fund.

Unravel Biosciences licenses Wyss Institute platform technology from Harvard and Tufts University to decode, model, and treat complex diseases

Retrieved on: 
Tuesday, September 27, 2022
Nervous system, Health, Bioinspiration, Swimming, Seizure, Wyss Institute, Department, Brain, Sepsis, CRISPR, Hospital, TMA, Gene, Intellectual, Population, Applied science, Lists of diseases, Senior, Degenerative disease, Judah, Partnership, Industry, Research, Harvard University, Patient, Infection, Physiology, Intelligence, Proteome, Transcriptome, Technology, Rett syndrome, Biology, CEO, Â, CSO, Head, Diagnosis, Tufts University, Drug development, Wyss, Behavior, Wyss Institute for Biologically Inspired Engineering, Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard Medical School, Lead, GLOBE, Vannevar Bush, Drug discovery, DARPA, Disease, Anatomy, Pharmaceutical industry, Dentistry, Engineering

Boston, MA, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Today, Unravel Biosciences and the Wyss Institute for Biologically Inspired Engineering at Harvard University announced that Unravel has licensed a drug discovery platform technology from Harvard and Tufts University.

Key Points: 
  • Boston, MA, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Today, Unravel Biosciences and the Wyss Institute for Biologically Inspired Engineering at Harvard University announced that Unravel has licensed a drug discovery platform technology from Harvard and Tufts University.
  • The company will use the technology, invented at the Wyss Institute, to decode and model complex diseases to accelerate the development of new and more effective therapies.
  • In contrast, we start with an individual patient and ask, What is different about this patient thats causing this disease?
  • Components of the CogniXense platform are being further developed at the Wyss Institute, and are being used in its Biostasis and CircaVent projects.

Harvard Wyss Institute’s eRapid multiplexed biosensor technology licensed to StataDX to enable new diagnostics for neurological, cardiovascular, and renal diseases

Retrieved on: 
Monday, June 27, 2022
Diagnosis, OTD, Patient, Ageing, Research, Biofouling, GLOBE, COVID-19, Wyss Institute for Biologically Inspired Engineering, Blood, Industry, Hormone, Heart failure, Neurology, Sport, Commonwealth, Degenerative disease, Therapy, Efficiency, NFL, Wyss Institute, Population, Bioinspiration, DARPA, Diabetes, RNA, Chronic kidney disease, Fluid mechanics, Time, CEO, Protein, Conditional sentence, Harvard Medical School, Kidney, Multiple sclerosis, Harvard University, Wyss, Harvard John A. Paulson School of Engineering and Applied Sciences, Hospital, Technology, Fingerstick, Gaps, Institute, Biomarker, Applied science, Ingber, Antibody, CTO, Pharmacy, Pharmaceutical industry, Medical imaging, Management, Medical device, Engineering

Wyss Institute for Biologically Inspired Engineering at Havard University, June 27, 2022 (GLOBE NEWSWIRE) -- (BOSTON) Today the Wyss Institute for Biologically Inspired Engineering at Harvard University and Cambridge-based StataDX Inc. announce that the Wyss Institutes affinity-based, multiplexed, electrochemical sensing technology, eRapid , has been licensed to the startup.

Key Points: 
  • Wyss Institute for Biologically Inspired Engineering at Havard University, June 27, 2022 (GLOBE NEWSWIRE) -- (BOSTON) Today the Wyss Institute for Biologically Inspired Engineering at Harvard University and Cambridge-based StataDX Inc. announce that the Wyss Institutes affinity-based, multiplexed, electrochemical sensing technology, eRapid , has been licensed to the startup.
  • The license, coordinated by Harvards Office of Technology Development (OTD), grants StataDX exclusive worldwide access to the eRapid technology in the fields of neurological, cardiovascular, and renal diseases.
  • These ultimately could result in life-changing and life-saving outcomes for patients with a vast range of diseases.
  • Biofouling poses a pervasive challenge to the development of electrochemistry-based diagnostics, which could be used to solve important diagnostic problems.

Trestle Biotherapeutics Announces Formation of Advisory Board

Retrieved on: 
Wednesday, February 23, 2022
Biotechnology, Hospitals, Genetics, Health, Entrepreneurship, Massachusetts General Hospital, Harvard Medical School, Faculty, Wyss Institute, Eli, Bionics, Kidney, Department, Hospital, University, Tissue engineering, Laboratory, Wyss Institute for Biologically Inspired Engineering, Transplant, Stem cell, Engineering, Nephrology, Regenerative medicine, Coronavirus Scientific Advisory Board (Turkey), Patient, Harvard University, Drug discovery, Wyss, AV, HAV, Developmental biology, Bioinspiration, Kidney failure, Protalix BioTherapeutics, CEO, Pharmaceutical industry, Management, Brigham, Trestle bridge

Trestle Biotherapeutics, a private, San Diego-based company developing bioengineered therapies for patients living with kidney failure today announced the formation of its advisory board.

Key Points: 
  • Trestle Biotherapeutics, a private, San Diego-based company developing bioengineered therapies for patients living with kidney failure today announced the formation of its advisory board.
  • The Trestle Advisory Board is a balanced mix of academic and industry leaders who are world renowned scientific experts in the fields of 3D biofabrication, stem cell and developmental biology, tissue engineering, immunology, and nephrology.
  • The composition of our advisory board reflects that approach, and we are proud to have them join us and help guide the effort, said Ben Shepherd, Co-Founder and CEO of Trestle.
  • In addition, Laura Niklason, M.D., Ph.D., Co-Founder and CEO of Humacyte has agreed to join the Trestle advisory board.

Trestle Biotherapeutics Licenses Innovations from Harvard University to Develop 3D Biofabricated Tissues to Treat Kidney Failure

Retrieved on: 
Tuesday, February 8, 2022
Research, General Health, University, Genetics, Education, Public Relations, Investor Relations, Clinical Trials, Science, Biotechnology, Communications, Other Science, Health, Kidney, Bioinspiration, Harvard John A. Paulson School of Engineering and Applied Sciences, Developmental biology, Harvard Medical School, Solution, Protalix BioTherapeutics, Wyss, Technology, Patient, Faculty, Applied science, Survival, Tissue, Bionics, CEO, SEAS, Hospital, Wyss Institute for Biologically Inspired Engineering, Therapy, Entrepreneurship, Kidney failure, Dialysis, Regenerative medicine, Harvard University, Laboratory, Massachusetts General Hospital, Nature, Transplant, Wyss Institute, Pharmaceutical industry, Dentistry, Engineering, Trestle bridge, Brigham, Yoshiko Morizane, DRS

Trestle Biotherapeutics , a private company based in San Diego, today announced that it has entered into a license agreement with Harvard University.

Key Points: 
  • Trestle Biotherapeutics , a private company based in San Diego, today announced that it has entered into a license agreement with Harvard University.
  • Trestle is developing functional kidney tissue to supplement and replace lost renal function in kidney failure patients.
  • Trestle is building these novel tissue therapeutics through the integration of stem cell biology and 3D biofabrication technologies.
  • Trestle was founded with the belief that recreating patterns and processes found in nature is key to building functional tissues.

Susan Tousi Joins Vizgen as Scientific Advisor

Retrieved on: 
Tuesday, November 30, 2021
Science, Health, Oncology, Research, Harvard University, Journal of Cellular and Molecular Medicine, Genomics, CEO, National academy, Central Waqf Council, Cell, Neuroscience, Technology, Disease, Industry, Wyss Institute, Bionics, Health, SAB, Kodak, Engineering, Developmental biology, G.H. Raisoni Department of Microbiology and Biotechnology, Running, Department, COVID-19, Invention, Hewlett-Packard, Howard Hughes Medical Institute, Wyss Institute for Biologically Inspired Engineering, Twitter, Research, Fortune, Diversity, Social media, Efficiency, Hospital, Bioinspiration, Data visualization, Drug discovery, Assistant, LinkedIn, Molecular medicine, Infection, Harvard Medical School, Growth, National Academy of Engineering, Management, Medical imaging, MERSCOPE, Vizgen, MERSCOPE, VIZGEN

In addition to Vizgens current scientific consultants, Susan Tousi, Chief Commercial Officer at Illumina, will join the SAB.

Key Points: 
  • In addition to Vizgens current scientific consultants, Susan Tousi, Chief Commercial Officer at Illumina, will join the SAB.
  • The Vizgen Scientific and Technical Advisory Board brings together a group of world-class leaders in life sciences technology to address the growing demand for single-cell spatial genomics research, said Terry Lo, President and CEO of Vizgen.
  • Susan Tousi brings to Vizgens SAB more than 25 years of R&D and business leadership experience at Fortune 100 technology companies, most recently in the life sciences industry.
  • Currently at Illumina , Susan oversees global sales, commercial operations, and commercial strategy and enablement.

Quanterix Co-Inventor of Simoa® David Walt Receives Kabiller Prize in Nanoscience and Nanomedicine

Retrieved on: 
Monday, November 8, 2021
Technology, Research, Medical Devices, Hospitals, Nanotechnology, Clinical Trials, Biotechnology, Health, Science, Quality of life, Population, Bioinspiration, Achievement, Biomarker, Neurology, Science, Private Securities Litigation Reform Act, News, Engineering, Medicine, U.S. Securities and Exchange Commission, Northwestern University, NASDAQ, CEO, Longevity, Disease, Hospital, Bionics, Technology, Inflammation, Infection, Harvard Medical School, Blood, Nanotechnology, Lists of diseases, Research, Cardiology, Forward-looking statement, Risk, Pathology, Corporation, Biology, DNA, Medical imaging

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, has announced that David Walt, co-inventor of Simoa, was awarded the Kabiller Prize in Nanoscience and Nanomedicine by Northwestern University .

Key Points: 
  • Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, has announced that David Walt, co-inventor of Simoa, was awarded the Kabiller Prize in Nanoscience and Nanomedicine by Northwestern University .
  • The Quanterix team sends our heartfelt congratulations to David on receiving the prestigious Kabiller Prize in Nanoscience and Nanomedicine, said Kevin Hrusovsky, Chairman and CEO, Quanterix Corporation.
  • As an integral part of Quanterix innovative, ultrasensitive biomarker detection platform, Simoa, were honored to see firsthand the far-reaching and meaningful impact of Davids work.
  • Walt also played an integral role in the development of Quanterix core digital immunoassay platform, Simoa, and the creation of Illumina, Inc.s microwell-based DNA array.

India Medical Technology Market Report 2021-2025: Major Players are Opto Circuits, Philips, Siemens, TTK Healthcare, and Appasamy Associates - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 6, 2021
General Health, Medical devices, Other Health, Health, Managed care, Biological engineering, Articles, Biotechnology, Life sciences, Bioinspiration, Bionics, Medical device, Disposable product, Health sciences

The medical technology market comprises players supplying health devices and instruments, diagnostic equipment and reagents, bionics, implants, disposables, and consumables.

Key Points: 
  • The medical technology market comprises players supplying health devices and instruments, diagnostic equipment and reagents, bionics, implants, disposables, and consumables.
  • While the demand for personal protective equipment rose steeply, the supply side was massively constrained due to lockdown measures.
  • The revenue fell sharply in the first quarter of FY 2021 due to a drop in sales volume for Non-COVID-19 items.
  • Patient aids and others is expected to be the fastest-growing segment during the forecast period.\nAn increase in demand for new applications has led to the growth of medical technology market.